Rigel to Present at Keystone Symposia Conference

Saturday, January 24, 2009 General News
Email Print This Page Comment
Font : A-A+

SOUTH SAN FRANCISCO, Calif., Jan. 23 RigelPharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will bepresenting at the Keystone Symposia conference on Multiple Sclerosis takingplace this week in Santa Fe, New Mexico.

Presentation Date: Sunday, January 25, 2009

Time: 2:30 - 4:30pm

Session: Workshop 2: New Therapeutic Approaches to MS

Presentation Title: The orally bioavailable Protein Kinase C InhibitorRGE-80 can abrogate EAE disease induction and ameliorates disease in atherapeutic setting

About Rigel (http://www.rigel.com)

Rigel is a clinical-stage drug development company that discovers anddevelops novel, small-molecule drugs for the treatment ofinflammatory/autoimmune diseases and cancer, as well as viral and metabolicdiseases. Our pioneering research focuses on intracellular signaling pathwaysand related targets that are critical to disease mechanisms. Rigel'sproductivity has resulted in strategic collaborations with largepharmaceutical partners to develop and market our product candidates. Rigelhas product development programs in inflammatory/autoimmune diseases such asrheumatoid arthritis, thrombocytopenia and asthma, as well as in cancer.

Contact: Raul Rodriguez

Phone: 650.624.1302

Email: invrel@rigel.com

SOURCE Rigel Pharmaceuticals, Inc.


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Advertisement
Advertisement

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook